Brokerages Raise Targets on Manipal Health Growth
Following Manipal Health’s second-quarter results, brokerages have adopted a more optimistic stance, with JPMorgan upgrading its rating and several others boosting their earnings forecasts and price targets, driven by confidence in the company’s growth prospects.
JPMorgan has revised its rating for Manipal Health from ‘Neutral’ to ‘Overweight’, and increased its target price from Rs 800 to Rs 820. According to the brokerage, the swift integration of Sahyadri Hospitals and rising occupancy rates are key factors contributing to enhanced profitability and operational efficiency. Notably, Manipal’s newer hospitals in Bengaluru are nearing EBITDA margins of 24-25%, which reinforces the effectiveness of its expansion strategy. JPMorgan has also increased its EBITDA estimates for FY27-FY29 by 5%, citing improved execution and cooperation benefits from recent acquisitions.
Read Also: Faculty members offered industry fellowship grants
HSBC has retained its ‘Buy’ rating, with a target price of Rs 880. The brokerage anticipates sustained growth driven by volume expansion, supported by the addition of clinical teams and improving profitability at Sahyadri. Manipal plans to add 550-600 beds by FY28 and is exploring the development of a new 500-bed hospital in Gurugram. HSBC has raised its earnings estimates for FY27, FY28, and FY29 by 6.9%, 1.8%, and 1.1%, respectively, highlighting the importance of capacity expansion and cost efficiency in driving growth.
Jefferies has reaffirmed its ‘Buy’ recommendation and increased its target price from Rs 870 to Rs 900. The brokerage notes that volume-driven growth remained robust during the September quarter, with Karnataka being a major contributor. Revenue and EBITDA growth were fueled by higher patient volumes, improved performance in core clusters, and the scaling up of new facilities. Jefferies observes that Sahyadri’s margins have improved by 200 basis points, as integration efforts progress, and the company’s expansion plans remain on track. In light of the stronger outlook, Jefferies has raised its FY27-FY29 EBITDA estimates by 2-3%.
Read Also: China Intel Allegations Lag Behind Public Narrative
Kotak Institutional Equities has maintained its ‘Add’ rating and increased its target price from Rs 730 to Rs 760. The brokerage characterizes the quarter as a strong volume-driven performance, supported by the continued improvement in Manipal’s CONGO-R mix, which now stands at approximately 64%, contributing to higher average revenue per occupied bed. Kotak expects the addition of around 2,400 new beds in the coming years, with about 40% of these additions concentrated in core markets. The brokerage also anticipates profitability improvements at acquired hospital networks, including AMRI, Medica, and Sahyadri.
Brokerages forecast compound annual growth rates of approximately 17% and 20% for revenue and EBITDA, respectively, over FY26-FY29. They note that Manipal’s relatively low oncology mix limits the impact of the government’s 30% trade-margin cap on oncology drugs, although potential future expansion of the cap to medical consumables remains a risk factor. Overall, brokerages remain confident in Manipal Health’s ability to sustain growth through capacity additions, improving occupancy levels, and successful integration of recent acquisitions, making it a preferred choice in India’s hospital sector.